Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 2/20 | 0.39 |
| ▸ | CPT2 | P23786 | 2/20 | 0.39 |
| ▸ | CPT1A | P50416 | 2/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13415458 | 0.87 | CACNA1H (0.52) | CACNA1HNR4A2KDM4EKMT2AMAOB | |
| SCHEMBL13415459 | 0.81 | NR4A2 (0.64) | CACNA1HNR4A2KDM4EKMT2AMAOB | |
| SCHEMBL6590142 | 0.80 | MAPT (0.51) | CACNA1HNR4A2KDM4EKMT2AMAOB | |
| SCHEMBL8355113 | 0.79 | KMT2A (0.63) | NR4A2KDM4EKMT2AMAOBCDK2 | |
| SCHEMBL13415462 | 0.77 | ALDH1A1 (0.49) | CACNA1HNR4A2KDM4EKMT2AMAOB | |
| SCHEMBL3131370 | 0.77 | FLT1 (0.47) | KDM4EKMT2AERAP1 | |
| SCHEMBL9572754 | 0.76 | KCNH2 (0.59) | CACNA1HNR4A2KDM4EKMT2AMAOB | |
| SCHEMBL8356629 | 0.75 | NR4A2 (0.64) | NR4A2KDM4EKMT2A | |
| SCHEMBL13114466 | 0.75 | KDM4E (0.64) | CACNA1HNR4A2KDM4EKMT2AMAOB | |
| SCHEMBL4419843 | 0.74 | KMT2A (0.50) | CACNA1HNR4A2KDM4EKMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| WO-2008095908-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | CCR9, IDO1, CCR10 | CACNA1H 2656/4885NR4A2 2827/4885KDM4E 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.